http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9624065-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34c7b34102e745f5a7ab0f6f6cb3aa91 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 |
| filingDate | 1996-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_095275e2ea39ae390019e2c14981ba2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc7c53f922ffd58588dcbff5fe9d55b3 |
| publicationDate | 1996-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9624065-A1 |
| titleOfInvention | Methods for the detection of pro-cathepsins and uses thereof |
| abstract | This invention is directed to a method of prognosis for a breast cancer patient involving quantitatively detecting pro-cathepsin B, D, or L in a sample of a bodily fluid which may include plasma, serum, urine, saliva, lymphatic fluids, whole blood, or nipple aspirates. The detection of pro-cathepsin may be performed utilizing a cathepsin binding agent as a capture agent. The binding agent may be monoclonal or polyclonal antibodies specific for pro-cathepsin or an enzyme inhibitor such as pepstain. The prognosis may involve the likelihood of recurrence of cancer, of relapse, or of survival. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9830907-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0169260-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0169260-A2 |
| priorityDate | 1995-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.